Publicaciones en colaboración con investigadores/as de Cincinnati Children's Hospital Medical Center (29)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  3. Efficacy of T-cell assays for the diagnosis of primary defects in cytotoxic lymphocyte exocytosis

    Blood, Vol. 144, Núm. 8, pp. 873-887

  4. Stroke in critically ill patients with respiratory failure due to COVID-19: Disparities between low-middle and high-income countries

    Heart and Lung, Vol. 68, pp. 131-144

2023

  1. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

2022

  1. Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors

    Pediatric Blood and Cancer, Vol. 69, Núm. 1

  2. Src kinase as a potential therapeutic target in non-alcoholic and alcoholic steatohepatitis

    Clinical and Translational Discovery, Vol. 2, Núm. 1

2021

  1. Building consensus on definition and nomenclature of hepatic, pancreatic, and biliary organoids

    Cell Stem Cell, Vol. 28, Núm. 5, pp. 816-832

  2. Functional Ability and Health-Related Quality of Life in Randomized Controlled Trials of Tocilizumab in Patients With Juvenile Idiopathic Arthritis

    Arthritis Care and Research, Vol. 73, Núm. 9, pp. 1264-1274

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis

    Rheumatology (United Kingdom), Vol. 60, Núm. 10, pp. 4568-4580

  5. Tapering Canakinumab Monotherapy in Patients With Systemic Juvenile Idiopathic Arthritis in Clinical Remission: Results From a Phase IIIb/IV Open-Label, Randomized Study

    Arthritis and Rheumatology, Vol. 73, Núm. 2, pp. 336-346

2020

  1. Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: Analysis by the Pharmachild Safety Adjudication Committee

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  2. Vaginal metabolome: towards a minimally invasive diagnosis of microbial invasion of the amniotic cavity in women with preterm labor

    Scientific Reports, Vol. 10, Núm. 1

2019

  1. A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor

    Cancer Cell, Vol. 36, Núm. 1, pp. 51-67.e7

  2. American College of Rheumatology Provisional Criteria for Clinically Relevant Improvement in Children and Adolescents With Childhood-Onset Systemic Lupus Erythematosus

    Arthritis Care and Research, Vol. 71, Núm. 5, pp. 579-590

  3. Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study

    The Lancet Child and Adolescent Health, Vol. 3, Núm. 4, pp. 255-263

2018

  1. KDM6B overexpression activates innate immune signaling and impairs hematopoiesis in mice

    Blood Advances, Vol. 2, Núm. 19, pp. 2491-2504

2017

  1. Biomarkers of cardiovascular stress and fibrosis in preclinical hypertrophic cardiomyopathy

    Open Heart, Vol. 4, Núm. 2

  2. The molecular pathogenesis of the NUP98-HOXA9 fusion protein in acute myeloid leukemia

    Leukemia